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In this issue of Cell Metabolism, Aronova et al. (2008) show that target of rapamycin complex 2 (TORC2)
controls de novo ceramide synthesis in yeast by regulating the activity of ceramide synthase. This work
may provide insight into how chemotherapeutic drugs increase de novo ceramide synthesis and promote
cell death in humans.Sphingolipids, glycerophospholipids, and
sterols are the major lipid constituents of
eukaryotic membranes whose concentra-
tion is tightly controlled. Mechanisms for
controlling the levels of glycerophospholi-
pids and sterols are well established, but
the mechanisms for regulating sphingoli-
pid synthesis await elucidation. In this is-
sue of Cell Metabolism, Powers and col-
leagues (Aronova et al., 2008) describe
studies in the baker’s yeast Saccharomy-
ces cerevisiae showing that target of ra-
pamycin complex 2 (TORC2) controls de
novo synthesis of ceramides, key mole-
cules in cellular life and death decisions
and the precursors to complex sphingoli-
pids found in membranes.
TOR is a conserved protein kinase that
senses nutrients and stresses and coordi-
nates metabolism both temporarily and
spatially tocontrol cell growth (Wullschleger
et al., 2006). Eukaryotes contain two TOR
protein complexes: TORC1, which is in-
hibited by rapamycin, and TORC2, which
is rapamycin insensitive. The key cellular
roles played by the TOR complexes have
led to the hypothesis that new inhibitors
could provide superior treatments for can-
cer, cardiovascular and autoimmune dis-
eases, and metabolic disorders.
Knowledge of its genomic sequence and
the ease with which it can be genetically
manipulatedhavemadeS. cerevisiaean in-
valuable organism for identifying genes that
encode sphingolipid metabolic enzymes
(Dickson and Lester, 2002; Sims et al.,
2004), and genetic selection procedures
provided the first hint of a connection be-
tween sphingolipids and the TOR signaling
network. While studying calcium homeo-
stasis in yeast, Beeler and Dunn isolated
amutation in theCSG2 gene that conferred
sensitivity to calcium (Beeler et al., 1998).
CSG2 encodes a subunit of the enzyme
for converting inositol phosphoceramide(IPC; Figure 1) to mannose-IPC (MIPC). A
screen for temperature-sensitivemutations
bypassing the calcium sensitivity of csg2
mutant cells identified several genes, but
two, TOR2 and AVO3/TSC11, which en-
code components of TORC2,wereparticu-
larly enticing (Beeler et al., 1998). TORC2
subunits, including the Avo3 homolog Ric-
tor, are well conserved in mammals.
The early steps in sphingolipid synthesis
are fairly well conserved (Figure 1) and ini-
tiate with the condensation of serine and
fatty acyl-CoAs, most often C16-CoA, to
yield 3-ketodihydrosphingosine, a type of
sphingolipid long-chain base (LCB). Re-
duction yields the LCB dihydrosphingo-
sine (DHS, sphinganine), whose amine
group is acylated by the enzyme ceramide
synthase (acyl-CoA: sphingosine N-acyl-
transferase) to produce dihydroceramide.
In fungi and plants (Dickson and Lester,
2002), the DHS in dihydroceramide is
changed by hydroxylation to phytosphin-
gosine (PHS) to generate phytoceramide.
In contrast, mammals change the DHS in
dihydroceramide to the LCB sphingosine
by making a double bond between C4
and C5 to generate ceramide. A species-
specific array of sugars and other polar
groups are added to ceramide and phyto-
ceramide to produce complex sphingoli-
pids found primarily, but not exclusively,
in the plasma membrane. Phytoceramide
in S. cerevisiae is modified with inositol
phosphate to produce IPC (Figure 1), fol-
lowed by addition of mannose to generate
MIPC, which is modified by addition of
a second inositol phosphate to produce
mannose-(IP)2-ceramide (M(IP)2C).
To elucidate the connection between
TOR signaling and sphingolipids, Aronova
et al. (2008) isolated an allele of AVO3
(avo3-30) that diminished growth at
30C. This was advantageous because
previous alleles required higher tempera-Cell Metabolistures to reduce growth, and high temper-
atures are a concern since they enhance
DHS, PHS, and ceramide levels (Dickson
et al., 2006), which might mask the effect
of an avo3 mutation on ceramide synthe-
sis. At 25C, avo3-30 cells grew like
wild-type cells, but their growth slowed
within 5–6 hr after a shift to 30C. Aronova
et al. found that 3 hr after shifting avo3-30
cells to 30C, the concentration of the
major yeast ceramide species containing
PHS and a C26 fatty acid was reduced 5-
fold compared towild-type cells. The level
of minor ceramide species with shorter
fatty acid chains was reduced about
10-fold. The concentration of the major
ceramides was even reduced 2-fold in
avo3-30 cells grown at 25C. Taken to-
gether, these data indicated that avo3-
30 cells had reduced ceramide synthase
activity, a prediction that was confirmed
by measuring enzyme activity in micro-
somes isolated from cells grown at 30C.
How does TORC2 affect ceramide
synthase activity? Aronova et al. focused
on the Ypk2 protein kinase because it is
activated by TORC2 and because mutant
ypk2 and avo3-30 cells show similar
defects in cell-wall integrity and actin
polarization. Insightful data were obtained
by using a constitutively active allele of
YPK2 that reversed all mutant phenotypes
in avo3-30 cells, including the ceramide
deficiency. Thus, it seems likely that Ypk2
works downstream of TORC2 to activate
ceramide synthase activity (Figure 1).
Future studies will need to determine
whether Ypk2 directly phosphorylates
a subunit of ceramide synthase to govern
enzyme activity or whether another Ypk2
substrate regulates this activity.
Another interesting finding involved
calcineurin, an evolutionarily conserved
Ca2+/calmodulin-regulated protein phos-
phatase that downregulates cellularm 7, February 2008 ª2008 Elsevier Inc. 99
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synthesisof complex sphingolipids (Mulet
et al., 2006; Tabuchi et al., 2006). Aronova
et al. found that deleting the CNB1
gene, which encodes the calcineurin
regulatory subunit B, restored ceramide
levels in avo3-30 cells and promoted
growth at 30C. This finding suggests
that calcineurin downregulates ceramide
synthase activity (Figure 1), but the mo-
lecular mechanism is unknown. Deletion
of CNB1 did not, however, restore actin
polarization, implying that it is controlled
by TORC2 in a manner distinctly differ-
ent from ceramide synthesis activity.
Previous work had shown that blocking
steps in sphingolipid synthesis down-
stream of DHS and PHS causes their
accumulation, and Aronova et al. found
that mutant avo3-30 cells indeed accu-
mulate these LCBs. DHS and PHS are
known to activate the Pkh1 and Pkh2 pro-
tein kinases, which along with TORC2 ac-
tivate Ypk2 (Dickson et al., 2006). Thus,100 Cell Metabolism 7, February 2008 ª2008Aronova et al. speculate that LCBs act in
a feed-forward manner to coregulate
Ypk2 along with TORC2, thereby control-
ling ceramide synthase activity and the
flux of LCBs that are incorporated into ce-
ramides and complex sphingolipids.
These studies in yeast begin to reveal
how cells promote ceramide and sphingo-
lipid synthesis when conditions favor
growth and how they reduce synthesis
when stresses impede growth. Because
the early steps in de novo sphingolipid
synthesis are reasonably conserved,
mammalian TORC2may play a role in reg-
ulating de novo ceramide synthesis. How-
ever, mammals have at least six ceramide
synthases that make ceramides with fatty
acids of a particular chain length (Pewz-
ner-Jung et al., 2006). The enzymes also
display unique temporal and cell-specific
expression patterns. Given this diversity,
it is unlikely that mTORC2 regulates all of
these enzymes, but it could govern some
in certain cell types. The mammalian or-Elsevier Inc.tholog of Ypk2 is the serum glucocorti-
coid-inducible protein kinase SGK, which
may transmit the signal from mTORC2 to
some ceramide synthases. But it would
not be surprising if other members of the
AGC kinase family, including Akt/PKB,
transmitted the mTORC2 signal to ceram-
ide synthases, since Akt/PKB functions
downstream of mTORC2 (Wullschleger
et al., 2006). Mammalian ceramide syn-
thases are already receiving much atten-
tion, but the yeast results should stimulate
a more focused interest and may pave the
way to understanding how de novo ce-
ramide synthesis is regulated inmammals.
Such understanding could lead to better
chemotherapeutic drugs, some of which
promote apoptosis by enhancing de novo
ceramide synthesis in ways that are not
currently understood (Bose et al., 1995;
Senkal et al., 2007).
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(2006). Cell 124, 471–484.Figure 1. De Novo Ceramide and Sphingolipid Synthesis Is Regulated by TORC2 in Yeast
Initial steps in sphingolipid synthesis up through formation of dihydroceramide are fairly well conserved
in eukaryotes including the baker’s yeast Saccharomyces cerevisiae and mammals. TORC2 in yeast
senses growth signals and activates the protein kinase Ypk2, which then activates ceramide synthase.
The Ca2+/calmodulin-regulated protein phosphatase calcineurin opposes the TORC2-Ypk2 pathway to
downregulate ceramide synthase activity.
